NANPING, China, Jan. 11, 2021 /PRNewswire/ -- Happiness Biotech
Group Limited (the "Company" or Nasdaq: HAPP), an innovative
China-based nutraceutical and
dietary supplements producer, announced today that Happy Buy, the
Company's wholly-owned subsidiary focusing on e-commerce business,
has achieved over 70% growth in December
2020, on a month-on-month basis. The total sales of Happy
Buy in December has reached over $5.5
million compared with approximately $3 million in November.
"Thanks to the hard work of our Happy Buy team, we created
continued momentum and again delivered great results in December.
We are also very happy that we have attracted investors from the
e-commerce industry this month. We believe that with the funds
raised from these investors and the dedication of our Happy Buy
team, Happy Buy will achieve more rapid development in the future.
Meanwhile, we have another exciting news – we anticipate Happy Buy
International to be launched around April, 2021. Overseas consumers
will have also access to our services and products offered by Happy
Buy in the near future," said Mr. Xuezhu
Wang, CEO of the Company.
About Happiness Biotech Group Limited
Headquartered in Nanping, China, Happiness Biotech Group Limited is an
innovative China-based
nutraceutical and dietary supplements producer focused on the
research, development, manufacturing and marketing of a variety of
products made from Chinese herbal extracts and other ingredients.
The Company's goal is to provide high-quality products to our
consumers. Over the past 14 years, the Company has established a
product portfolio consisting of 32 PRC National Medical Products
Administration registered "Blue-Cap" SKUs of nutraceutical and
dietary supplements products. For more information, please
visit: www.happ.org.cn.
Forward-Looking Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions;
reputation and brand; the impact of competition and pricing;
government regulations; fluctuations in general economic and
business conditions in China, the
COVID-19 outbreak and its impact on our operations and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the Securities and
Exchange Commission. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the U.S.
Securities and Exchange Commission, which are available for review
at www.sec.gov. The Company undertakes no obligation to publicly
revise these forward-looking statements to reflect events or
circumstances that arise after the date hereof.
View original
content:http://www.prnewswire.com/news-releases/happiness-biotechs-e-commerce-business---happy-buy-achieved-over-70-growth-in-december-301205120.html
SOURCE Happiness Biotech Group Limited